← All candidates
Two insider buys in the last year — $1000.0K in all.
21 filings on record.
PTHSPelthos Therapeutics Inc.
NYSE American · Healthcare · $92.28M
$20.32
-7.38% · Sep 15
Two insider buys in the last year — $1000.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 5 sells◆ 8 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what PTHS ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$92.28M
Float
1.4M
40% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
3.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Davis Todd C
Bought $985.5K on Jun 11 — 35,445 sh @ $27.80, held direct, 47% of their stake.
No completed positions to measure
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
13 more transactions on Pro →Context
Wall St
$57.71 avg target
+184.0% vs today · 7 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$4.66 act−$1.08
Q4 '25−$2.69 act+$1.50
Q3 '25−$5.30 act−$4.72
Q2 '25−$5.38 act+$0.88
The file stays open
21 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice